메뉴 건너뛰기




Volumn 35, Issue 7, 2015, Pages 447-453

The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EDOXABAN; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

EID: 84971674248     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0298-2     Document Type: Article
Times cited : (80)

References (18)
  • 1
    • 49849099533 scopus 로고    scopus 로고
    • DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles
    • Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-9.
    • (2008) J Thromb Haemost , vol.6 , Issue.9 , pp. 1542-1549
    • Furugohri, T.1    Isobe, K.2    Honda, Y.3    Kamisato-Matsumoto, C.4    Sugiyama, N.5    Nagahara, T.6
  • 2
    • 84971609136 scopus 로고    scopus 로고
    • Daiichi Sankyo Company, Ltd
    • Lixiana (edoxaban tosilate hydrate tablets): full prescribing information. Tokyo: Daiichi Sankyo Company, Ltd.; 2014.
    • (2014) Full Prescribing Information. Tokyo
  • 3
    • 80053580161 scopus 로고    scopus 로고
    • Parsippany: Daiichi Sankyo Inc
    • SavaysaTM (edoxaban) tablets for oral use: full prescribing information. Parsippany: Daiichi Sankyo Inc.; 2015.
    • (2015) Full Prescribing Information
  • 4
    • 77953787643 scopus 로고    scopus 로고
    • Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor
    • Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitoredoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-53.
    • (2010) J Clin Pharmacol , vol.50 , Issue.7 , pp. 743-753
    • Ogata, K.1    Mendell-Harary, J.2    Tachibana, M.3    Masumoto, H.4    Oguma, T.5    Kojima, M.6
  • 5
    • 84869109465 scopus 로고    scopus 로고
    • Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans
    • Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250-5.
    • (2012) Drug Metab Dispos , vol.40 , Issue.12 , pp. 2250-2255
    • Bathala, M.S.1    Masumoto, H.2    Oguma, T.3    He, L.4    Lowrie, C.5    Mendell, J.6
  • 7
    • 84885129987 scopus 로고    scopus 로고
    • Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
    • Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331-42.
    • (2013) Am J Cardiovasc Drugs , vol.13 , Issue.5 , pp. 331-342
    • Mendell, J.1    Zahir, H.2    Matsushima, N.3    Noveck, R.4    Lee, F.5    Chen, S.6
  • 8
    • 84983074820 scopus 로고    scopus 로고
    • Rockville: US Food and Drug Administration
    • Center for Drug Evaluation and Research. Guidance for industry-safety testing of drug metabolites. Rockville: US Food and Drug Administration; 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
    • (2012) Guidance for Industry-Safety Testing of Drug Metabolites
  • 9
    • 0029916534 scopus 로고    scopus 로고
    • P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
    • Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci. 1996;93(9):4001-5.
    • (1996) Proc Natl Acad Sci , vol.93 , Issue.9 , pp. 4001-4005
    • Schuetz, E.G.1    Schinkel, A.H.2    Relling, M.V.3    Schuetz, J.D.4
  • 11
    • 0036293982 scopus 로고    scopus 로고
    • Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
    • Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164-72.
    • (2002) Hepatology , vol.36 , Issue.1 , pp. 164-172
    • Vavricka, S.R.1    Van Montfoort, J.2    Ha, H.R.3    Meier, P.J.4    Fattinger, K.5
  • 14
    • 84983026166 scopus 로고    scopus 로고
    • Sanofi-Aventis, US, LLC
    • Rifadin rifampin capsules USP: package insert. Bridgewater: Sanofi-Aventis, US, LLC; 2013. Available at http://products.sanofi.us/rifadin/Rifadin.pdf.
    • (2013) Package Insert. Bridgewater
  • 15
    • 0030911953 scopus 로고    scopus 로고
    • Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
    • Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61(5):544-53.
    • (1997) Clin Pharmacol Ther , vol.61 , Issue.5 , pp. 544-553
    • Borin, M.T.1    Chambers, J.H.2    Carel, B.J.3    Gagnon, S.4    Freimuth, W.W.5
  • 16
    • 84862107719 scopus 로고    scopus 로고
    • Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice
    • Zhang Y, Cheng X, Aleksunes L, Klaassen CD. Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice. Drug Metab Dispos. 2012;40(6):1191-7.
    • (2012) Drug Metab Dispos , vol.40 , Issue.6 , pp. 1191-1197
    • Zhang, Y.1    Cheng, X.2    Aleksunes, L.3    Klaassen, C.D.4
  • 17
    • 33644843888 scopus 로고    scopus 로고
    • Roles of rifampicin in drug-drug interactions: Underlying molecular mechanisms involving the nuclear pregnane X receptor
    • Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5:3
    • (2006) Ann Clin Microbiol Antimicrob , vol.5
    • Chen, J.1    Raymond, K.2
  • 18
    • 33751160865 scopus 로고    scopus 로고
    • Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism
    • Lam JL, Shugarts SB, Okochi H, Benet LZ. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther. 2006;319(2):864-70
    • (2006) J Pharmacol Exp Ther , vol.319 , Issue.2 , pp. 864-870
    • Lam, J.L.1    Shugarts, S.B.2    Okochi, H.3    Benet, L.Z.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.